BioSpace News Archive

According to Precedence Research, the global biomarkers market is expected to grow from its estimated value of USD 63.06 billion in 2021 to USD 207.46 billion by the end of 2030. This represents an excellent CAGR of 14.1% from 2021 to 2030.

The global genomics market was estimated at USD 21.06 billion in 2021 and is expected to surpass USD 72.13 billion by 2030, growing at a CAGR of 13.65% between 2021 and 2030.

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and YonaLink, a clinical trial software provider, announced having completed an initial funding round, raising $6 million, to scale global growth and expand YonaLink’s EHR-to-EDC integration platform.

ALPINION Medical Systems, a leading brand in ultrasound technology and state-of-the-art medical equipment manufacturer, will present a new range of high-performance diagnostic equipment at the Radiological Society of North America’s radiology conference and annual meeting.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2022 and provided an update on key corporate milestones.

T2 Biosystems, Inc. announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York.

Trevena, Inc. announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-25.

Ipsen announced the Phase III NAPOLI 3 trial of Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma and key secondary efficacy outcome of progression-free survival also showed significant improvement over the comparator arm.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three and nine months ended September 30, 2022.

IsoPlexis Corporation, a company empowering labs to leverage the cells and proteome changing the course of human health, announced it will be participating in the following investor conferences.